Zacks Ranks stocks can, and often do, change throughout the month. Bayer AG has acquired BlueRock Therapeutics from Versant Ventures for up to $1 billion. ZacksTrade and Zacks.com are separate companies. View Company. When factoring in the strength of its earnings outlook, BRG looks like an impressive value stock at the moment.At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. BlueRock, a biotech, focuses on stem cell research. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. Find the latest Bluerock Residential Growth REI (BRG) stock quote, history, news and other vital information to help you with your stock trading and investing. BlueRock Therapeutics financials. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.As an alternative to using this form, you can send us your name and zacks account email with your request to privacy@zacks.com.These are only a few of the key metrics included in Bluerock's strong Value grade, but they help show that the stock is likely undervalued right now. Recommended this to investors, however, only concern is extension of the lock down. Competitors. Provider of biotechnology services intended to focus on stem-cell research. Summary - Funding Rounds. While London South East do their best to maintain the high quality of the information displayed on this site, we cannot be held responsible for any loss due to incorrect information found here. It has a market capitalisation of £3m, with approximately 9m shares in issue. Within the past 52 weeks, BRG's P/B has been as high as 3.19 and as low as 1.05, with a median of 2.44.For 32 years, our Strong Buy list has averaged returns more than twice the market. These returns cover a period from January 1, 1988 through July 6, 2020. Using our novel GPCR heterodimer targeting approach, we are able to achieve up to 50x the painkilling potency of morphine, but without addictive side effects. BlueRock Therapeutics Stock. Value investors will be interested in the system's "Value" category. 0.
The monthly returns are then compounded to arrive at the annual return.
Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. Company profile page for BlueRock Therapeutics LP including stock price, company news, press releases, executives, board members, and contact information This compares to its industry's average Forward P/E of 21.08.